不同剂量瑞舒伐他汀对 ACS 患者血清炎症因子及血管内皮功能的影响

目的：探讨不同剂量瑞舒伐他汀对急性冠状动脉综合征（ACS）患者血清炎症因子及血管内皮功能的影响。方法：选择符合标准的患者80例，采用随机数字表法分为观察组和对照组各40例，在基础上观察组每晚口服瑞舒伐他汀片20mg，对照组服用10mg，治疗前及治疗后12周检测内皮素1（ET－1）、一氧化氮（NO）、超敏 C－反应蛋白（hs－CRP）、人基质金属蛋白酶9（MMP－9）和纤溶酶原激活抑制剂－1（PAI－1）水平，记录心血管事件。结果：治疗前，两组患者血清 ET－1、NO、hs－CRP、MMP－9及PAI－1水平相似，差异无统计学意义（P＞0．05）；治疗12周后，两组患者血清 ET－1、hs－CRP、MMP－9及PAI－1水平较本组治疗前下降，而 NO 水平上升，两组比较差异有统计学意义（P＜0．05）。治疗期间，观察组患者心血管事件发生率10．00％，低于对照组的32．50％，差异有统计学意义（P＜0．05）。结论：瑞舒伐他汀能减少 ACS 患者血清炎症因子合成和释放，改善和保护血管内皮功能，减少心血管事件发生率，提高治疗效果，强化治疗的作用更显著。

Effects of Different Dosages of Rosuvastatain on the Vascular Endothelium Function and Serum Inflammatory Factor in Patients with ACS

Objective: To investigate the effects of different dosages of rosuvastatain on the vascular en -dothelium function and serum inflammatory factor in patients with acute coronary syndrome (ACS).Methods:A total of 80 eligible patients were selected and randomly divided into observation group and control group , with 40 patients in each group.Based on the fundamental treatments, the observation group used Rosuvastatain Tablets, 20mg po qn, additionally, while the control group used it at 10mg po qn.Before the treatment and at after 12w treatment, the levels of endothelin-1 (ET-1), nitric oxide (NO), hypersensitive C reactive pro-tein (hs-CRP), human matrix metalloproteinase (MMP), and plasminogen activator inhibitor -1 (PAI-1) were measured, and cardiovascular events were recorded .Results:Before the treatments, the patients of the two groups had insignificantly different serum levels of ET -1, NO, hs-CRP, MMP-9, and PAI-1 (P>0. 05); after 12w treatment, the patients of both groups had significantly decreased serum levels of ET -1, hs-CRP, MMP-9, and PAI-1 and significantly increased serum NO levels compared with those before the treat -ments, but the observation group had significantly greater improving extents (P<0.05).In the treatment peri-od, the incidence of cardiovascular events of the observation group was 10.00%, and was significantly lower than that of the control group (32.50%) (P<0.05).Conclusion: Rosuvastatain can decrease the synthesis and release of serum inflammatory factors , improve and protect vascular endothelium function , reduce the inci-dence of cardiovascular events, and elevate the efficacy, and has significant effects of intensification therapy in ACS patients.